Clinical Trials

NCL SubtypeSponsorInterventionStatusLink to Trial Info
CLN1JCR PharmaceuticalsAGT-194 enzyme replacement IVInvestigator-led study – 1 patient treated (Germany). Study no longer active. R&D actively continues.
Seeking to initiate collaborative CLN1 natural history study.
CLN1Taysha Gene TherapiesTSH-118 Gene therapy (AAV9; CNS)Ph 1/2 paused (since early 2022)
Continuing to explore partnership opportunities

Single patient dosed under investigator-initiated study at RUSH, Chicago. Joint Statement to the Global Batten Disease Community (Feb. 2024).
CLN2BioMarinCerliponase alfa - enzyme replacement; CNSFDA Approves BRINEURA® for Children Under 3 Years with CLN2 Disease (July 2024)

NCT04476862 Ph 4 -Observational/safety, ongoing (USA)
https://clinicaltrials.gov/study/NCT04476862
CLN2BioMarinCerliponase alfa - OcularNCT05152914 Ph 1/2 - Active, not recruiting (USA)https://clinicaltrials.gov/study/NCT05152914
CLN2Tern TherapeuticsTTX-381 Gene therapy (AAV9; ocular)Tern Therapeutics Receives US FDA Fast Track Designation for TTX-381 Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease (April 2025)

U.K. MHRA Awards Tern Therapeutics Innovation Passport for TTX-381 to Accelerate Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease (July 2025)
CLN2Tern TherapeuticsTTX-181 Gene therapy (AAV9; CNS)https://www.terntx.com/services-7
CLN3University of North Carolina (UNC) Hospitals and ForeBatten FoundationFBF-001 (Zebronkysen); Antisense Oligonucleotide (ASO)N-of-2 study currently active. (Commenced Sept. 2024)

One-Year Update (July 2025)
https://www.forebatten.org/zebronkysen

https://news.unchealthcare.org/2024/09/unc-fast-tracks-personalized-treatment-for-twins-with-ultra-rare-genetic-disorder/
CLN3Alcyone TherapeuticsCLN-301 Gene therapy (AAV9; CNS)Formerly licenced to Amicus Therapeutics (until February 2024).

*APRIL 2025 UPDATE* Alcyone Therapeutics Advances Pipeline for CLN-301 Gene Therapy for CLN3 Batten Disease
https://clinicaltrials.gov/study/NCT03770572
CLN3Beyond Batten Disease Foundation/TheranexusBatten-1 (miglustat)NCT05174039 Ph 1/2 - complete (USA)
Ph 3 pediatric study expected to commence 2025 (international sites)

Theranexus and BBDF Share Strong Positive Real-World Data Supporting Batten-1 Efficacy for the Treatment of CLN3 Disease (May 2025)
https://clinicaltrials.gov/study/NCT05174039
CLN3Polaryx TherapeuticsPLX-200 (gemfibrozil)NCT04637282 Ph 3 - not yet recruiting
(no movement since Nov 2020) - No update at this time
https://clinicaltrials.gov/study/NCT04637282
CLN5NeurogeneNGN-101 Gene therapy (AAV9; CNS & ocular)NCT05228145 Ph 1/2 Active; not recruiting (USA & UK)

FDA RMAT Application denied, Neurogene evaluating best path forward for the program
(Nov. 2024)

Neurogene continues to evaluate best path forward for NGN-101 program (July 2025 - BDSRA Annual Family Conference)
https://clinicaltrials.gov/study/NCT05228145
CLN6Amicus TherapeuticsAT-GTX-501 Gene therapy (AAV9; CNS)(Program formerly with Amicus Therapeutics)

Gray Foundation and Children's Hospital of Orange County (CHOC) Announce the Relaunch of CLN6 Gene Therapy Program (May 2025)
CLN7UT Southwestern/Elpida TherapeuticsGene therapy (AAV9; CNS) Elpida TherapeuticsNCT04737460 Ph1 active; not recruiting (USA)
Assessments ongoing;
Planning underway to move to Phase 2 (Elpida Therapeutics).
https://clinicaltrials.gov/study/NCT04737460

Natural History Studies

NCL SubtypeSponsorInterventionStatusLink to Trial Info
Natural History Study - all NCL typesUniversity of Rochester, NYAll NCL typesNCT01873924 recruiting international patients – in-person and/or virtual visits
Natural History Study - CLN3 onlyNational Institutes of Health (NIH)CLN3; biomarker studyNCT03307304 recruiting international patients – in-person visits (+ virtual visits)
Natural History Study - all NCL typesUKE Hamburg-Eppendorf, GermanyAll NCL typesNCT04613089 recruiting international patients – in-person and/or virtual visits